Clinic4U OÜ

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis8 trials
• CIDP (chronic inflammatory demyelinating polyneuropathy)3 trials
• Alzheimer disease1 trial

Phase

• Phase 311 trials
• Phase 21 trial

Status

• Recruiting6 trials
• Active, not recruiting4 trials
• Completed2 trials

Lead sponsor

• argenx2 trials
• Novartis Pharma AG2 trials
• Zenas BioPharma (USA), LLC2 trials
• Hoffmann-La Roche1 trial
• Immunic AG1 trial
• and 4 more

Running trials

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· argenx· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· argenx· Source

• Recruiting

  Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT07032662· Phase 2· Immunovant Sciences GmbH· Source

• Active, not recruiting

  A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

  NCT05123703· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

  NCT05201638· Phase 3· Immunic AG· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

  NCT05156281· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis

  2024-511686-11-00· Phase 3· Novartis Pharma AG· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• CIDP (chronic inflammatory demyelinating polyneuropathy)3 recruiting
• Multiple sclerosis3 recruiting

Closed trials

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT04408755· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source